Pharmacological profiles of cloned mammalian P2Y-receptor subtypes

Pharmacology and Therapeutics

Volumn 110, Issue 3, 2006, Pages 415-432

  von Kügelgen, Ivar ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Cangrelor; Clopidogrel; MRS2179; MRS2279; MRS2567; P2Y receptor; Prasugrel; Subtype selective antagonists

Indexed keywords

1,2 DI (4 ISOTHIOCYANATOPHENYL)ETHANE; 2 CHLORO N 6 METHYL (N) METHANOCARBA 2' DEOXYADENOSINE 3,5 BISPHOSPHONATE; 2 IODO N 6 METHYL (N) METHANOCARBA 2' DEOXYADENOSINE 3',5' BISPHOSPHONATE; 2 PROPYLTHIO BETA,GAMMA DICHLOROMETHYLENE; 2 PROPYLTHIO BETA,GAMMA DICHLOROMETHYLENE D ADENOSINE TRIPHOSPHATE; 2' DEOXY 6 N METHYLADENOSINE 3',5' BISPHOSPHATE; 2' DEOXY N 6 METHYLADENOSINE 3',5' BISPHOSPHONATE; 2,2 DIMETHYL PROPIONIC ACID 3 (2 CHLORO 6 METHYLAMINOPURIN 9 YL) 2 (2,2 DIMETHYL PROPIONYLOXYMETHYL)PROPYL ESTER; 3 [7 [2 (3,4 DIFLUOROPHENYL)CYCLOPROPYLAMINO] 5 PROPYLTHIO 1,2,3 TRIAZOLO[4,5 D]PYRIMIDIN 3 YL] 5 HYDROXYMETHOXY 1,2 CYCLOPENTANEDIOL; 6 (2' CHLORO 5' NITRO AZOPHENYL)PYRIDOXAL ALPHA5 PHOSPHATE; 6 (2' CHLORO AZOPHENYL)PYRIDOXAL ALPHA5 PHOSPHATE; 8 8' [CARBONYLBIS(IMINO 3,1 PHENYLENE)]BIS (1,3,5 NAPHTHALENE TRISULFONATE; ADENOSINE DERIVATIVE; ARC 67085; BETA,GAMMA DICHLOROMETHYLENE 2 PROPYLTHIOADENOSINE TRIPHOSPHATE; CANGRELOR; CLOPIDOGREL; DENUFOSOL; DIQUAFOSOL; MRS 2210; MRS 2211; MRS 2279; MRS 2365; MRS 2395; MRS 2500; MRS 2567; N 6 (2 METHYLTHIOETHYL) 2 (3,3,3 TRIFLUOROPROPYLTHIO)BETA,GAMMA DICHLOROMETHYLENE ADENOSINE TRIPHOSPHATE; N METHANOCARBA 2 METHYLTHIO ADENOSINE DIPHOSPHATE; NF 023; NUCLEOSIDE DERIVATIVE; PRASUGREL; PURINE P2Y RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; PURINERGIC RECEPTOR STIMULATING AGENT; PYRIDOXAL PHOSPHATE 6 AZOPHENYL 2',4' DISULFONIC ACID; RECEPTOR SUBTYPE; SURAMIN; TICLOPIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERLUKAST;

AMINO ACID COMPOSITION; AMINO TERMINAL SEQUENCE; CELL DIFFERENTIATION; CHLORIDE TRANSPORT; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; DRY EYE; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE LOCATION; GENE SEQUENCE; GLYCOSYLATION; HUMAN; LYMPHOCYTE; MOLECULAR CLONING; NERVE CELL; NEUROMODULATION; NONHUMAN; NUCLEOTIDE SEQUENCE; ORTHOLOGY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN LOCALIZATION; RESPIRATORY EPITHELIUM; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; TISSUE LEVEL; UNINDEXED SEQUENCE; VASODILATATION;

AMINO ACID SEQUENCE; ANIMALS; CLONING, MOLECULAR; HUMANS; LIGANDS; MOLECULAR SEQUENCE DATA; RECEPTORS, PURINERGIC P2; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY;

EID: 33646424353     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2005.08.014     Document Type: Review

References (215)

1. Abbracchio M.P., Boeynaems J.M., Barnard E.A., Boyer J.L., Kennedy C., Miras-Portugal M.T., et al. Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) adds diversity to the P2Y receptor family. Trends Pharmacol Sci 24 (2003) 52-55
2. Abbracchio M.P., and Burnstock G. Purinoceptors: Are there families of P2X and P2Y purinoceptors?. Pharmacol Ther 64 (1994) 445-475
3. Abbracchio M.P., Burnstock G., Boeynaems J.M., Barnard E.A., Boyer J.L., Kennedy C., et al. The recently deorphanized GPR80 (GPR99) proposed to be the P2Y15 receptor is not a genuine P2Y receptor. Trends Pharmacol Sci 26 (2005) 8-9
4. Adrian K., Bernhard M.K., Breitinger H.G., and Ogilvie A. Expression of purinergic receptors (ionotropic P2X1-7 and metabotropic P2Y1-11) during myeloid differentiation of HL60 cells. Biochim Biophys Acta 1492 (2000) 127-138
5. Alvarado-Castillo C., Harden T.K., and Boyer J.L. Regulation of P2Y1 receptor-mediated signaling by the ectonucleoside triphosphate diphosphohydrolase isozymes NTPDase1 and NTPDase2. Mol Pharmacol 67 (2005) 114-122
6. 1 receptor and NTPDase1 exhibits functional activities of the native receptor and ectoenzyme and reduced signaling responses to endogenously released nucleotides. Mol Pharmacol 62 (2002) 521-528
7. 1 purinoceptor. Biochem Biophys Res Commun 218 (1996) 783-788
8. Barnard E.A., Burnstock G., and Webb T.E. G protein-coupled receptors for ATP and other nucleotides: a new receptor family. Trends Pharmacol Sci 15 (1994) 67-70
9. Barnard E.A., Simon J., and Webb T.E. Nucleotide receptors in the nervous system. An abundant component using diverse transduction mechanisms. Mol Neurobiol 15 (1997) 103-129
10. Belous A., Wakata A., Knox C.D., Nicoud I.B., Pierce J., Anderson C.D., et al. Mitochondrial P2Y-Like receptors link cytosolic adenosine nucleotides to mitochondrial calcium uptake. J Cell Biochem 92 (2004) 1062-1073
11. Bender E., Buist A., Jurzak M., Langlois X., Baggerman G., Verhasselt P., et al. Characterization of an orphan G protein-coupled receptor localized in the dorsal root ganglia reveals adenine as a signaling molecule. Proc Natl Acad Sci U S A 99 (2002) 8573-8578
12. Bläsius R., Weber R.G., Lichter P., and Ogilvie A. A novel orphan G protein-coupled receptor primarily expressed in the brain is localized on human chromosomal band 2q21. J Neurochem 70 (1998) 1357-1365
13. Bodor E.T., Waldo G.L., Hooks S.B., Corbitt J., Boyer J.L., and Harden T.K. Purification and functional reconstitution of the human P2Y12 receptor. Mol Pharmacol 64 (2003) 1210-1216
14. Bogdanov Y.D., Dale L., King B.F., Whittock N., and Burnstock G. Early expression of a novel nucleotide receptor in the neural plate of Xenopus embryos. J Biol Chem 272 (1997) 12583-12590
15. 4 nucleotide receptor. Br J Pharmacol 124 (1998) 428-430
16. 1 receptor antagonist. Br J Pharmacol 135 (2002) 2004-2010
17. 6-methyl 2′-deoxyadenosine 3′,5′-bisphosphate. Br J Pharmacol 124 (1998) 1-3
18. 1 receptor. Mol Pharmacol 50 (1996) 1323-1329
19. Burnstock G. The past, present and future of purine nucleotides as signalling molecules. Neuropharmacology 36 (1997) 1127-1139
20. Burnstock G., and Knight G.E. Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol 240 (2004) 31-304
21. Burnstock G., and Warland J.J. P2-purinoceptors of two subtypes in the rabbit mesenteric artery: Reactive blue 2 selectively inhibits responses mediated via the P2y-but not the P2x-purinoceptor. Br J Pharmacol 90 (1987) 383-391
22. 1 receptors. J Med Chem 41 (1998) 183-190
23. Cantagrel V., Lossi A.M., Boulanger S., Depetris D., Mattei M.G., Gecz J., et al. Disruption of a new X linked gene highly expressed in brain in a family with two mentally retarded males. J Med Genet 41 (2004) 736-742
24. Cattaneo M., Lecchi A., Ohno M., Joshi B.V., Besada P., Tchilibon S., et al. Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor. Biochem Pharmacol 68 (2004) 1995-2002
25. Cattaneo M., Zighetti M.L., Lombardi R., Martinez C., Lecchi A., Conley P.B., et al. Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding. Proc Natl Acad Sci U S A 100 (2003) 1978-1983
26. Chambers J.K., Macdonald L.E., Sarau H.M., Ames R.S., Freeman K., Foley J.J., et al. A G protein-coupled receptor for UDP-glucose. J Biol Chem 275 (2000) 10767-10771
27. 2 nucleotide receptor. J Biol Chem 270 (1995) 26152-26158
28. 2U-purinoceptors. Br J Pharmacol 118 (1996) 704-710
29. 4 receptors: Characterization of a suramin and PPADS-insensitive response to UTP. Br J Pharmacol 119 (1996) 1301-1303
30. Charlton M.E., Williams A.S., Fogliano M., Sweetnam P.M., and Duman R.S. The isolation and characterization of a novel G protein-coupled receptor regulated by immunologic challenge. Brain Res 764 (1997) 141-148
31. Chen Z.P., Krull N., Xu S., Levy A., and Lightman S.L. Molecular cloning and functional characterization of a rat pituitary G protein-coupled adenosine triphosphate (ATP) receptor. Endocrinology 137 (1996) 1833-1840
32. Chhatriwala M., Ravi R.G., Patel R.I., Boyer J.L., Jacobson K.A., and Harden T.K. Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog. J Pharmacol Exp Ther 311 (2004) 1038-1043
33. Colquhoun D. Binding, gating, affinity and efficacy: The interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br J Pharmacol 125 (1998) 924-947
34. Communi D., and Boeynaems J.M. Receptors responsive to extracellular pyrimidine nucleotides. Trends Pharmacol Sci 18 (1997) 83-86
35. Communi D., Pirotton S., Parmentier M., and Boeynaems J.M. Cloning and functional expression of a human uridine nucleotide receptor. J Biol Chem 270 (1995) 30849-30852
36. 4 receptor. Eur J Pharmacol 317 (1996) 383-389
37. 6 receptor. Biochem Biophys Res Commun 222 (1996) 303-308
38. Communi D., Govaerts C., Parmentier M., and Boeynaems J.M. Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase. J Biol Chem 272 (1997) 31969-31973
39. 11 receptor. Br J Pharmacol 128 (1999) 1199-1206
40. i. J Biol Chem 276 (2001) 41479-41485
41. Communi D., Suarez-Huerta N., Dussossoy D., Savi P., and Boeynaems J.M. Cotranscription and intergenic splicing of human P2Y11 and SSF1 genes. J Biol Chem 276 (2001) 16561-16566
42. Costanzi S., Mamedova L., Gao Z.G., and Jacobson K.A. Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling. J Med Chem 47 (2004) 5393-5404
43. - transport. J Biol Chem 274 (1999) 26461-26468
44. Diaz-Hernandez M., Pintor J., and Miras-Portugal M.T. Modulation of the dinucleotide receptor present in rat midbrain synaptosomes by adenosine and ATP. Br J Pharmacol 130 (2000) 434-440
45. Diaz-Hernandez M., Pintor J., Castro E., and Miras-Portugal M.T. Independent receptors for diadenosine pentaphosphate and ATP in rat midbrain single synaptic terminals. Eur J Neurosci 14 (2001) 918-926
46. Diaz-Hernandez M., Sanchez-Nogueiro J., Pintor J., and Miras-Portugal M.T. Interaction between dinucleotide and nicotinic receptors in individual cholinergic terminals. J Pharmacol Exp Ther 311 (2004) 954-967
47. Ding Z., Kim S., Dorsam R.T., Jin J., and Kunapuli S.P. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood 101 (2003) 3908-3914
48. Ding Z., Tuluc F., Bandivadekar K.R., Zhang L., Jin J., and Kunapuli S.P. Arg333 and Arg334 in the COOH terminus of the human P2Y1 receptor are crucial for Gq coupling. Am J Physiol Cell Physiol 288 (2005) C559-C567
49. Dorsam R.T., and Kunapuli S.P. Central role of the P2Y12 receptor in platelet activation. J Clin Invest 113 (2004) 340-345
50. Dranoff J.A., O'Neill A.F., Franco A.M., Cai S.Y., Connolly G.C., Ballatori N., et al. A primitive ATP receptor from the little skate Raja erinacea. J Biol Chem 275 (2000) 30701-30706
51. Dunn P.M., and Blakeley A.G. Suramin: A reversible P2-purinoceptor antagonist in the mouse vas deferens. Br J Pharmacol 93 (1988) 243-245
52. 12 receptor in nucleotide inhibition of exocytosis from bovine chromaffin cells. Mol Pharmacol 66 (2004) 601-611
53. 2U purinoceptors. Positively charged amino acids in transmembrane helices 6 and 7 affect agonist potency and specificity. J Biol Chem 270 (1995) 4185-4188
54. 2U purinergic receptor. Proc Natl Acad Sci U S A 90 (1993) 10449-10453
55. Erlinge D., Hou M., Webb T.E., Barnard E.A., and Moller S. Phenotype changes of the vascular smooth muscle cell regulate P2 receptor expression as measured by quantitative RT-PCR. Biochem Biophys Res Commun 248 (1998) 864-870
56. 1-deficient mice. Nat Med 5 (1999) 1199-1202
57. 2+ channel in neurones, with both adenosine triphosphates and diphosphates as potent agonists. Br J Pharmacol 129 (2000) 1063-1066
58. Firestein B.L., Xing M., Hughes R.J., Corvera C.U., and Insel P.A. Heterogeneity of P2u- and P2y-purinergic receptor regulation of phospholipases in MDCK cells. Am J Physiol 271 (1996) F610-F618
59. Fischer W., Wirkner K., Weber M., Eberts C., Koles L., Reinhardt R., et al. Characterization of P2X3, P2Y1 and P2Y4 receptors in cultured HEK293-hP2X3 cells and their inhibition by ethanol and trichloroethanol. J Neurochem 85 (2003) 779-790
60. Foster C.J., Prosser D.M., Agans J.M., Zhai Y., Smith M.D., Lachowicz J.E., et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 107 (2001) 1591-1598
61. Fredholm B.B., Abbracchio M.P., Burnstock G., Dubyak G.R., Harden T.K., Jacobson K.A., et al. Towards a revised nomenclature for P1 and P2 receptors. Trends Pharmacol Sci 18 (1997) 79-82
62. Fredriksson R., Lagerstrom M.C., Lundin L.G., and Schioth H.B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 63 (2003) 1256-1272
63. Freeman K., Tsui P., Moore D., Emson P.C., Vawter L., Naheed S., et al. Cloning, pharmacology, and tissue distribution of G-protein-coupled receptor GPR105 (KIAA0001) rodent orthologs. Genomics 78 (2001) 124-128
64. Fumagalli M., Trincavelli L., Lecca D., Martini C., Ciana P., and Abbracchio M.P. Cloning, pharmacological characterisation and distribution of the rat G-protein-coupled P2Y(13) receptor. Biochem Pharmacol 68 (2004) 113-124
65. Furchgott R.F. The classification of adrenoceptors (adrenergic receptors). An evaluation from the standpoint of receptor theory. In: Blaschko H., and Muscholl E. (Eds). Catecholamines. Handbook of Experimental Pharmacology (1972), Springer, Berlin 283-335
66. Gao Z.G., Mamedova L., Tchilibon S., Gross A.S., and Jacobson K.A. 2,2′-Pyridylisatogen tosylate antagonizes P2Y1 receptor signaling without affecting nucleotide binding. Biochem Pharmacol 68 (2004) 231-237
67. Gerevich Z., Borvendeg S.J., Schröder W., Franke H., Wirkner K., Nörenberg W., et al. Inhibition of N-type voltage-activated calcium channels in rat dorsal root ganglion neurons by P2Y receptors is a possible mechanism of ADP-induced analgesia. J Neurosci 24 (2004) 797-807
68. Gorzalka S., Vittori S., Volpini R., Cristalli G., von Kügelgen I., and Müller C.E. Evidence for the functional expression and pharmacological characterization of adenine receptors in native cells and tissues. Mol Pharmacol 67 (2005) 955-964
69. Guo D., von Kügelgen I., Moro S., Kim Y.C., and Jacobson K.A. Evidence for the recognition of non-nucleotide antagonists within the transmembrane domains of the human P2Y1 receptor. Drug Dev Res 57 (2002) 173-181
70. Hansmann G., Bültmann R., Tuluc F., and Starke K. Characterization by antagonists of P2-receptors mediating endothelium-dependent relaxation in the rat aorta. Naunyn Schmiedeberg's Arch Pharmacol 356 (1997) 641-652
71. Harden T.K., Lazarowski E.R., and Boucher R.C. Release, metabolism and interconversion of adenine and uridine nucleotides: Implications for G protein-coupled P2 receptor agonist selectivity. Trends Pharmacol Sci 18 (1997) 43-46
72. Häussinger D., Stehle T., and Gerok W. Actions of extracellular UTP and ATP in perfused rat liver: a comparative study. Eur J Biochem 167 (1987) 65-71
73. He W., Miao F.J., Lin D.C., Schwandner R.T., Wang Z., Gao J., et al. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature 429 (2004) 188-193
74. Hechler B., Cattaneo M., and Gachet C. The p2 receptors in platelet function. Semin Thromb Hemost 31 (2005) 150-161
75. Hechler B., Vigne P., Leon C., Breittmayer J.P., Gachet C., and Frelin C. ATP derivatives are antagonists of the P2Y1-receptor: similarities to the platelet ADP receptor. Mol Pharmacol 53 (1998) 727-733
76. Henderson D.J., Elliot D.G., Smith G.M., Webb T.E., and Dainty I.A. Cloning and characterisation of a bovine P2Y receptor. Biochem Biophys Res Commun 212 (1995) 648-656
77. Herbert J.M., Tissinier A., Defreyn G., and Maffrand J.P. Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits. Arterioscler Thromb 13 (1993) 1171-1179
78. Herold C.L., Qi A.D., Harden T.K., and Nicholas R.A. Agonist versus antagonist action of ATP at the P2Y4 receptor is determined by the second extracellular loop. J Biol Chem 279 (2004) 11456-11464
79. 1 receptor in surface expression and activation processes. J Biol Chem 274 (1999) 14639-14647
80. Hoffmann C., Soltysiak K., West P.L., and Jacobson K.A. Shift in purine/pyrimidine base recognition upon exchanging extracellular domains in P2Y 1/6 chimeric receptors. Biochem Pharmacol 68 (2004) 2075-2086
81. Hollopeter G., Jantzen H.M., Vincent D., Li G., England L., Ramakrishnan V., et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409 (2001) 202-207
82. Illes P., and Ribeiro J.A. Molecular physiology of P2 receptors in the central nervous system. Eur J Pharmacol 483 (2004) 5-17
83. Inbe H., Watanabe S., Miyawaki M., Tanabe E., and Encinas J.A. Identification and characterization of a cell-surface receptor, P2Y15, for AMP and adenosine. J Biol Chem 279 (2004) 19790-19799
84. Ingall A.H., Dixon J., Bailey A., Coombs M.E., Cox D., McInally J.I., et al. Antagonists of the platelet P2T receptor: A novel approach to antithrombotic therapy. J Med Chem 42 (1999) 213-220
85. Jacobson K.A., Costanzi S., Ohno M., Joshi B.V., Besada P., Xu B., et al. Molecular recognition at purine and pyrimidine nucleotide (P2) receptors. Curr Top Med Chem 4 (2004) 805-819
86. Jacobson K.A., Hoffmann C., Kim Y.C., Camaioni E., Nandanan E., Jang S.Y., et al. Molecular recognition in P2 receptors: Ligand development aided by molecular modeling and mutagenesis. Prog Brain Res 120 (1999) 119-132
87. Jacobson K.A., Jarvis M.F., and Williams M. Purine and pyrimidine (P2) receptors as drug targets. J Med Chem 45 (2002) 4057-4093
88. 1 receptor. Biochem Biophys Res Commun 221 (1996) 588-593
89. 2 receptor polymorphism: Identification and pharmacological characterization of two allelic variants. Br J Pharmacol 127 (1999) 709-716
90. 1 receptor. Mol Pharmacol 52 (1997) 499-507
91. Kaiser R.A., and Buxton I.L. Nucleotide-mediated relaxation in guinea-pig aorta: Selective inhibition by MRS2179. Br J Pharmacol 135 (2002) 537-545
92. Kanaoka Y., and Boyce J.A. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J Immunol 173 (2004) 1503-1510
93. Kauffenstein G., Hechler B., Cazenave J.P., and Gachet C. Adenine triphosphate nucleotides are antagonists at the P2Y receptor. J Thromb Haemost 2 (2004) 1980-1988
94. 2 receptor antagonists. Drug Dev Res 59 (2003) 72-81
95. Kennedy C., Assis T.S., Currie A.J., and Rowan E.G. Crossing the pain barrier: P2 receptors as targets for novel analgesics. J Physiol 553 (2003) 683-694
96. 4 receptor. Mol Pharmacol 57 (2000) 926-931
97. Khakh B.S., Burnstock G., Kennedy C., King B.F., North R.A., Seguela P., et al. International union of pharmacology: XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. Pharmacol Rev 53 (2001) 107-118
98. Kim Y.C., Lee J.S., Sak K., Marteau F., Mamedova L., Boeynaems J.M., et al. Synthesis of pyridoxal phosphate derivatives with antagonist activity at the P2Y13 receptor. Biochem Pharmacol 70 (2005) 266-274
99. 1 receptor antagonists. J Med Chem 46 (2003) 4974-4987
100. King B.F., Dacquet C., Ziganshin A.U., Weetman D.F., Burnstock G., Vanhoutte P.M., et al. Potentiation by 2,2′-pyridylisatogen tosylate of ATP-responses at a recombinant P2Y1 purinoceptor. Br J Pharmacol 117 (1996) 1111-1118
101. King B.F., Townsend-Nicholson A., and Burnstock G. Metabotropic receptors for ATP and UTP: Exploring the correspondence between native and recombinant nucleotide receptors. Trends Pharmacol Sci 19 (1998) 506-514
102. Kubista H., Lechner S.G., Wolf A.M., and Boehm S. Attenuation of the P2Y receptor-mediated control of neuronal Ca2+ channels in PC12 cells by antithrombotic drugs. Br J Pharmacol 138 (2003) 343-350
103. Kulick M.B., and von Kügelgen I. P2Y-receptors mediating an inhibition of the evoked entry of calcium through N-type calcium channels at neuronal processes. J Pharmacol Exp Ther 303 (2002) 520-526
104. Kunzelmann K., and Mall M. Pharmacotherapy of the ion transport defect in cystic fibrosis: Role of purinergic receptor agonists and other potential therapeutics. Am J Respir Med 2 (2004) 299-309
105. Lambrecht G. Design and pharmacology of selective P2-purinoceptor antagonists. J Auton Pharmacol 16 (1996) 314-344
106. Lambrecht G. Agonists and antagonists acting at P2X receptors: Selectivity profiles and functional implications. Naunyn-Schmiedeberg's Arch Pharmacol 362 (2000) 340-350
107. Lambrecht G., Braun K., Damer M., Ganso M., Hildebrandt C., Ullmann H., et al. Structure-activity relationships of suramin and pyridoxal-5′-phosphate derivatives as P2 receptor antagonists. Curr Pharm Des 8 (2002) 2371-2399
108. Lambrecht G., Friebe T., Grimm U., Windscheif U., Bungardt E., Hildebrandt C., et al. PPADS, a novel functionally selective antagonist of P2 purinoceptor-mediated responses. Eur J Pharmacol 217 (1992) 217-219
109. Laubinger W., Wang H., Welte T., and Reiser G. P2Y receptor specific for diadenosine tetraphosphate in lung: selective inhibition by suramin, PPADS, Ip5I, and not by MRS-2197. Eur J Pharmacol 468 (2003) 9-14
110. Lazarowski E.R., Rochelle L.G., O'Neal W.K., Ribeiro C.M., Grubb B.R., Zhang V., et al. Cloning and functional characterization of two murine uridine nucleotide receptors reveal a potential target for correcting ion transport deficiency in cystic fibrosis gallbladder. J Pharmacol Exp Ther 297 (2001) 43-49
111. 2U-purinoceptor: Potent activation by diadenosine tetraphosphate. Br J Pharmacol 116 (1995) 1619-1627
112. Lee D.K., Nguyen T., Lynch K.R., Cheng R., Vanti W.B., Arkhitko O., et al. Discovery and mapping of ten novel G protein-coupled receptor genes. Gene 275 (2001) 83-91
113. Leipziger J. Control of epithelial transport via luminal P2 receptors. Am J Physiol Renal Physiol 284 (2003) F419-F432
114. 1 receptor-null mice. J Clin Invest 104 (1999) 1731-1737
115. 1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett 403 (1997) 26-30
116. 1 purinoceptor. Gene 171 (1996) 295-297
117. 6 receptor. Mol Pharmacol 54 (1998) 541-546
118. 5 receptor, does not mediate nucleotide-promoted second messenger responses. Biochem Biophys Res Commun 236 (1997) 455-460
119. Lustig K.D., Shiau A.K., Brake A.J., and Julius D. Expression cloning of an ATP receptor from mouse neuroblastoma cells. Proc Natl Acad Sci U S A 90 (1993) 5113-5117
120. Maffrand J.P., Bernat A., Delebassee D., Defreyn G., Cazenave J.P., and Gordon J.L. ADP plays a key role in thrombogenesis in rats. Thromb Haemost 59 (1988) 225-230
121. Maier R., Glatz A., Mosbacher J., and Bilbe G. Cloning of P2Y6 cDNAs and identification of a pseudogene: Comparison of P2Y receptor subtype expression in bone and brain tissues. Biochem Biophys Res Commun 240 (1997) 298-302
122. Major D.T., and Fischer B. Molecular recognition in purinergic receptors: 1. A comprehensive computational study of the h-P2Y1-receptor. J Med Chem 47 (2004) 4391-4404
123. Major D.T., Nahum V., Wang Y., Reiser G., and Fischer B. Molecular recognition in purinergic receptors: 2. Diastereoselectivity of the h-P2Y1-receptor. J Med Chem 47 (2004) 4405-4416
124. Mamedova L.K., Joshi B.V., Gao Z.G., von Kügelgen I., and Jacobson K.A. Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. Biochem Pharmacol 67 (2004) 1763-1770
125. Marchese A., George S.R., Kolakowski Jr. L.F., Lynch K.R., and O'Dowd B.F. Novel GPCRs and their endogenous ligands: expanding the boundaries of physiology and pharmacology. Trends Pharmacol Sci 20 (1999) 370-375
126. Marteau F., Le Poul E., Communi D., Communi D., Labouret C., Savi P., et al. Pharmacological characterization of the human P2Y13 receptor. Mol Pharmacol 64 (2003) 104-112
127. Mathieu R., Baurand A., Schmitt M., Gachet C., and Bourguignon J.J. Synthesis and biological activity of 2-alkylated deoxyadenosine bisphosphate derivatives as P2Y(1) receptor antagonists. Bioorg Med Chem 12 (2004) 1769-1779
128. Mellor E.A., Frank N., Soler D., Hodge M.R., Lora J.M., Austen K.F., et al. Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells: functional distinction from CysLT1R. Proc Natl Acad Sci U S A 100 (2003) 11589-11593
129. Mellor E.A., Maekawa A., Austen K.F., and Boyce J.A. Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells. Proc Natl Acad Sci U S A 98 (2001) 7964-7969
130. Miras-Portugal M.T., Pintor J., and Gualix J. Ca2+ signalling in brain synaptosomes activated by dinucleotides. J Membr Biol 194 (2003) 1-10
131. 1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. J Med Chem 41 (1998) 1456-1466
132. 1 receptor. Biochemistry 38 (1999) 3498-3507
133. Müller C.E. P2-pyrimidinergic receptors and their ligands. Curr Pharm Des 8 (2002) 2353-2369
134. 1 receptor ligands. J Med Chem 43 (2000) 829-842
135. Nguyen T., Erb L., Weisman G.A., Marchese A., Heng H.H., Garrad R.C., et al. Cloning, expression, and chromosomal localization of the human uridine nucleotide receptor gene. J Biol Chem 270 (1995) 30845-30848
136. Nicholas R.A., Watt W.C., Lazarowski E.R., Li Q., and Harden K. Uridine nucleotide selectivity of three phospholipase C-activating P2 receptors: Identification of a UDP-selective, a UTP-selective, and an ATP- and UTP-specific receptor. Mol Pharmacol 50 (1996) 224-229
137. 12 receptor antagonist activity. Semin Thromb Hemost 31 (2005) 184-194
138. Noguchi K., Ishii S., and Shimizu T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem 278 (2003) 25600-25606
139. Nörenberg W., and Illes P. Neuronal P2X receptors: Localisation and functional properties. Naunyn-Schmiedeberg's Arch Pharmacol 362 (2000) 324-339
140. North R.A. Molecular physiology of P2X receptors. Physiol Rev 82 (2002) 1013-1067
141. North R.A. The P2X3 subunit: A molecular target in pain therapeutics. Curr Opin Investig Drugs 4 (2004) 833-840
142. North R.A., and Barnard E.A. Nucleotide receptors. Curr Opin Neurobiol 7 (1997) 346-357
143. O'Connor S.E., Dainty I.A., and Leff P. Further subclassification of ATP receptors based on agonist studies. Trends Pharmacol Sci 12 (1991) 137-141
144. 1 receptor expression in Xenopus oocytes. J Biol Chem 271 (1996) 29080-29087
145. 1 receptor. Mol Pharmacol 54 (1998) 1118-1123
146. 2U nucleotide receptor, a target for cystic fibrosis pharmacotherapy. Proc Natl Acad Sci U S A 91 (1994) 3275-3279
147. 6 cells. Eur J Pharmacol 430 (2001) 203-210
148. Pausch M.H., Lai M., Tseng E., Paulsen J., Bates B., and Kwak S. Functional expression of human and mouse P2Y12 receptors in Saccharomyces cerevisiae. Biochem Biophys Res Commun 324 (2004) 171-177
149. Pendergast W., Yerxa B.R., Douglass III J.G., Shaver S.R., Dougherty R.W., Redick C.C., et al. Synthesis and P2Y receptor activity of a series of uridine dinucleotide 5′-polyphosphates. Bioorg Med Chem Lett 11 (2001) 157-160
150. Pintor J., Diaz-Hernandez M., Gualix J., Gomez-Villafuertes R., Hernando F., and Miras-Portugal M.T. Diadenosine polyphosphate receptors. From rat and guinea-pig brain to human nervous system. Pharmacol Ther 87 (2000) 103-115
151. 11 receptors. Mol Pharmacol 60 (2001) 1375-1382
152. Ralevic V., and Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 50 (1998) 413-492
153. Ralevic V., and Burnstock G. Involvement of purinergic signaling in cardiovascular diseases. Drug News Perspect 16 (2003) 133-140
154. Reséndiz J.C., Feng S., Ji G., Francis K.A., Berndt M.C., and Kroll M.H. Purinergic P2Y12 receptor blockade inhibits shear-induced platelet phosphatidylinositol 3-kinase activation. Mol Pharmacol 63 (2003) 639-645
155. 2u-purinergic receptor. Am J Respir Cell Mol Biol 12 (1995) 27-32
156. 6 receptor. Eur J Pharmacol 329 (1997) 231-236
157. Rosner B.N., Bartholomew J.N., Gaines C.D., Riddle M.L., Everett H.A., Rulapaugh K.G., et al. Biochemical evidence for a P2Y-like receptor in Tetrahymena thermophila. J Comp Physiol A Sens Neural Behav Physiol 189 (2003) 781-789
158. Saitou N., and Nei M. The neighbor-joining method: A new method for reconstructing phylogenetic trees. Mol Biol Evol 4 (1987) 406-425
159. 1 purinoceptors. Neurosci Lett 284 (2000) 179-181
160. 12, a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 283 (2001) 379-383
161. 3H]-2-methylthio ADP to rat platelets-effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther 269 (1994) 772-777
162. Savi P., Pereillo J.M., Uzabiaga M.F., Combalbert J., Picard C., Maffrand J.P., et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84 (2000) 891-896
163. 1 receptor. Br J Pharmacol 121 (1997) 338-344
164. 35S]ATPαS binding proteins associated with G-proteins. Neurochem Int 34 (1999) 303-317
165. Schöneberg T., Schulz A., Grosse R., Schade R., Henklein P., and Schultz G. A novel subgroup of class I G-protein-coupled receptors. Biochim Biophys Acta 1446 (1999) 57-70
166. Schulz A., and Schöneberg T. The structural evolution of a P2Y-like G-protein-coupled receptor. J Biol Chem 278 (2003) 35531-35541
167. Shen J., Seye C.I., Wang M., Weisman G.A., Wilden P.A., and Sturek M. Cloning, up-regulation, and mitogenic role of porcine P2Y2 receptor in coronary artery smooth muscle cells. Mol Pharmacol 66 (2004) 1265-1274
168. 2Y purinoceptor. Eur J Pharmacol 291 (1995) 281-289
169. Simon J., Filippov A.K., Goransson S., Wong Y.H., Frelin C., Michel A.D., et al. Characterization and channel coupling of the P2Y(12) nucleotide receptor of brain capillary endothelial cells. J Biol Chem 277 (2002) 31390-31400
170. 6 purinoceptor gene and phylogenetic analysis of the P2y purinoceptor family. Genomics 44 (1997) 127-130
171. Soulet C., Sauzeau V., Plantavid M., Herbert J.M., Pacaud P., Payrastre B., et al. Gi-dependent and -independent mechanisms downstream of the P2Y12 ADP-receptor. J Thromb Haemost 2 (2004) 135-146
172. Southey M.C., Hammet F., Hutchins A.M., Paidhungat M., Somers G.R., and Venter D.J. Molecular cloning and sequencing of a novel human P2 nucleotide receptor. Biochim Biophys Acta 1309 (1996) 77-80
173. Suarez-Huerta N., Pouillon V., Boeynaems J., and Robaye B. Molecular cloning and characterization of the mouse P2Y4 nucleotide receptor. Eur J Pharmacol 416 (2000) 197-202
174. Sugidachi A., Asai F., Ogawa T., Inoue T., and Koike H. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol 129 (2000) 1439-1446
175. i-linked P2T antagonist, CS-747. Br J Pharmacol 132 (2001) 47-54
176. Takasaki J., Kamohara M., Saito T., Matsumoto M., Matsumoto S., Ohishi T., et al. Molecular cloning of the platelet P2T(AC) ADP receptor: Pharmacological comparison with another ADP receptor, the P2Y(1) receptor. Mol Pharmacol 60 (2001) 432-439
177. Tatemoto K., Hosoya M., Habata Y., Fujii R., Kakegawa T., Zou M.X., et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 251 (1998) 471-476
178. Tauber J., Davitt W.F., Bokosky J.E., Nichols K.K., Yerxa B.R., Schaberg A.E., et al. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea 23 (2004) 784-792
179. Tokuyama Y., Hara M., Jones E.M., Fan Z., and Bell G.I. Cloning of rat and mouse P2Y purinoceptors. Biochem Biophys Res Commun 211 (1995) 211-218
180. Tulapurkar M.E., Laubinger W., Nahum V., Fischer B., and Reiser G. Subtype specific internalization of P2Y1 and P2Y2 receptors induced by novel adenosine 5′-O-(1-boranotriphosphate) derivatives. Br J Pharmacol 142 (2004) 869-878
181. 12 antagonists. Semin Thromb Hemost 31 (2005) 195-204
182. 2Y purinoceptor using rhodopsin as template. Drug Des Discov 13 (1995) 133-154
183. Vasiljev K.S., Uri A., and Laitinen J.T. 2-Alkylthio-substituted platelet P2Y12 receptor antagonists reveal pharmacological identity between the rat brain Gi-linked ADP receptors and P2Y12. Neuropharmacology 45 (2003) 145-154
184. Vial C., Roberts J.A., and Evans R.J. Molecular properties of ATP-gated P2X receptor ion channels. Trends Pharmacol Sci 25 (2004) 487-493
185. 1 receptor tagged with green-fluorescent protein: High-affinity ligand recognition of adenosine diphosphates and triphosphates and selectivity identical to that of the wild-type receptor. Biochem Pharmacol 59 (2000) 791-800
186. von Kügelgen I., and Jacobson K.A. Blockade of P2Y6-receptors by diisothiocyanato-stilbene-disulfonic acid (DIDS) and analogues. Naunyn-Schmiedeberg's Arch Pharmacol 363 (2001) R34
187. 2 purinoceptor, in rabbit ear artery. Naunyn-Schmiedeberg's Arch Pharmacol 336 (1987) 556-560
188. von Kügelgen I., Kulick M., Bönisch H., Göthert M., and Brüss M. Cloning of the rat and mouse P2Y12-receptor from neuronal cells or tissues. Naunyn-Schmiedeberg's Arch Pharmacol 364 (2001) R30
189. von Kügelgen I., Nörenberg W., Meyer A., Illes P., and Starke K. Role of action potentials and calcium influx in ATP- and UDP-induced noradrenaline release from rat cultured sympathetic neurones. Naunyn-Schmiedeberg's Arch Pharmacol 359 (1999) 360-369
190. 2-receptors of sympathetic neuro-effector transmission in the mouse isolated vas deferens. Naunyn-Schmiedeberg's Arch Pharmacol 340 (1989) 522-532
191. 3H]-noradrenaline release in rabbit brain cortex slices by direct action at presynaptic adenosine A1-receptors. Naunyn-Schmiedeberg's Arch Pharmacol 346 (1992) 187-196
192. von Kügelgen I., and Wetter A. Molecular pharmacology of P2Y-receptors. Naunyn-Schmiedeberg's Arch Pharmacol 362 (2000) 310-323
193. Waldo G.L., Corbitt J., Boyer J.L., Ravi G., Kim H.S., Ji X.D., et al. Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist. Mol Pharmacol 62 (2002) 1249-1257
194. Waldo G.L., and Harden T.K. Agonist binding and Gq-stimulating activities of the purified human P2Y1 receptor. Mol Pharmacol 65 (2004) 426-436
195. 3H]adenine-binding sites in rat brain membranes. J Biochem (Tokyo) 137 (2005) 323-329
196. 3) activated preferentially by nucleoside diphosphates. Mol Pharmacol 50 (1996) 258-265
197. 4 receptor. J Neurochem 71 (1998) 1348-1357
198. Webb T.E., Simon J., Krishek B.J., Bateson A.N., Smart T.G., King B.F., et al. Cloning and functional expression of a brain G-protein-coupled ATP receptor. FEBS Lett 324 (1993) 219-225
199. White P.J., Webb T.E., and Boarder M.R. Characterization of a Ca2+ response to both UTP and ATP at human P2Y11 receptors: Evidence for agonist-specific signaling. Mol Pharmacol 63 (2003) 1356-1363
200. Wihlborg A.K., Wang L., Braun O.O., Eyjolfsson A., Gustafsson R., Gudbjartsson T., et al. ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol 24 (2004) 1810-1815
201. 2+ ions. Br J Pharmacol 140 (2003) 1177-1186
202. Wirkner K., Schweigel J., Gerevich Z., Franke H., Allgaier C., Barsoumian E.L., et al. Adenine nucleotides inhibit recombinant N-type calcium channels via G protein-coupled mechanisms in HEK 293 cells; involvement of the P2Y13 receptor-type. Br J Pharmacol 141 (2004) 141-151
203. Wittenberger T., Schaller H.C., and Hellebrand S. An expressed sequence tag (EST) data mining strategy succeeding in the discovery of new G-protein coupled receptors. J Mol Biol 307 (2001) 799-813
204. Xu B., Stephens A., Kirschenheuter G., Greslin A.F., Cheng X., Sennelo J., et al. Acyclic analogues of adenosine bisphosphates as P2Y receptor antagonists: Phosphate substitution leads to multiple pathways of inhibition of platelet aggregation. J Med Chem 45 (2002) 5694-5709
205. 2 receptor agonist for the treatment of cystic fibrosis. J Pharmacol Exp Ther 302 (2002) 871-880
206. Yokomizo T., Izumi T., Chang K., Takuwa Y., and Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 387 (1997) 620-624
207. Yoshioka K., Saitoh O., and Nakata H. Heteromeric association creates a P2Y-like adenosine receptor. Proc Natl Acad Sci U S A 98 (2001) 7617-7622
208. Yoshioka K., Saitoh O., and Nakata H. Agonist-promoted heteromeric oligomerization between adenosine A(1) and P2Y(1) receptors in living cells. FEBS Lett 523 (2002) 147-151
209. Zambon A.C., Hughes R.J., Meszaros J.G., Wu J.J., Torres B., Brunton L.L., et al. P2Y(2) receptor of MDCK cells: Cloning, expression, and cell-specific signaling. Am J Physiol Renal Physiol 279 (2000) F1045-F1052
210. 11 receptors in Madin Darby canine kidney cells. Mol Pharmacol 60 (2001) 26-35
211. Zhang F.L., Luo L., Gustafson E., Lachowicz J., Smith M., Qiao X., et al. ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999. J Biol Chem 276 (2001) 8608-8615
212. 13: Identification and characterization of a novel Galphai-coupled ADP receptor from human and mouse. J Pharmacol Exp Ther 301 (2002) 705-713
213. Zhong X., Kriz R., Seehra J., and Kumar R. N-linked glycosylation of platelet P2Y12 ADP receptor is essential for signal transduction but not for ligand binding or cell surface expression. FEBS Lett 562 (2004) 111-117
214. Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn-Schmiedeberg's Arch Pharmacol 362 (2000) 299-309
215. Ziyal R., Ziganshin A.U., Nickel P., Ardanuy U., Mutschler E., Lambrecht G., et al. Vasoconstrictor responses via P2X-receptors are selectively antagonized by NF023 in rabbit isolated aorta and saphenous artery. Br J Pharmacol 120 (1997) 954-960